Synapse - Population Sciences Research Program

Results (40)

Clinical Factors but not somatic mutations predict for survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplant: Analysis of the North American myelofibrosis transplant outcome (NAMTO) study

Meeting Abstract

Ajufo, H.; Derkach, A.; Rampal, R. K.; Famulare, C.; Nemirovsky, D.; Chervin, J.; Ho, V.; Gupta, V.; Viswabandya, A.; Deeg, H. J.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis

Meeting Abstract

Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
Blood (2023)

Fulltext@MSK | Save

A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation

Meeting Abstract

Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
Blood (2023)

Fulltext@MSK | Save

A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
Blood (2023)

Fulltext@MSK | Save

A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations

Meeting Abstract

Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
Blood (2023)

Fulltext@MSK | Save

Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma

Meeting Abstract

Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Precision lineage deconvolution in mixed phenotype acute leukemia using CITE-seq derived hematopoietic stages identifies lineage dynamics associated with treatment response

Meeting Abstract

Dilip, D.; Galera, P.; Nemirovsky, D.; Lallo, M.; Menghrajani, K.; Derkach, A.; Levine, R. L.; Koche, R.; Xiao, W.; Glass, J.
Blood (2023)

Fulltext@MSK | Save

E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial

Meeting Abstract

Bewersdorf, J. P.; Chandhok, N. S.; Watts, J. M.; Derkach, A.; Abdel-Wahab, O.; Stein, E. M.; Taylor, J.
Blood (2023)

Fulltext@MSK | Save

Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions

Meeting Abstract

Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
Blood (2023)

Fulltext@MSK | Save

Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades

Meeting Abstract

Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
Blood (2023)

Fulltext@MSK | Save